hotspot -WSS

hotspot

author：explore 2025-09-30 09:57:13 - browse：58

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： How the drug

entertainment

WSS

Hospital at home shows how to bring innovation to health care

As obesity drug market grows, telehealth companies court payers

Can U.S. cancer drug shortages be fixed?

PBMs are inflating the cost of generic drugs. They must be reined in

Study: Spinal cord stimulation helps patients with paralysis walk again

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

hotspot

hotspot

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Obesity now affects over 1 billion people worldwide, study finds

Continuity nursing helped my family in our darkest PICU moments

Abortion policy in the spotlight at Republican debate

In Memoriam: Notable people who died in 2023

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Sports medicine is finally prioritizing gender equality

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

BioMarin wins approval for gene therapy to treat hemophilia A

Meadows told special counsel he could not recall Trump ever declassifying Mar

hotspot

Republicans love RFK Jr. What's that tell us about health in 2024?

Pfizer highlights cancer drugs it thinks could reignite investor interest

Hospital at home shows how to bring innovation to health care

National associations that represent hospice owe an apology

Intellia plays down concerns on accidental germline transmission

Republicans love RFK Jr. What's that tell us about health in 2024?

entertainment

focus

entertainment

focus